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Abstract
Introduction: While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might
preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between
adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its
expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to
analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in
surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of ‘‘carcinoma NOS (not
otherwise specified)’’ in a prospective series of small tumor samples.
Methods: With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we
performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of
66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC.
Results: The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when
compared to ACs (p,0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all
P63 positive cases (34%) were diagnosed as SCCs.
Conclusions: P63 IHC is useful for the identification of lung SCCs.
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Introduction
The arrival, approximately a decade ago, of global gene
expression profiling studies meant an improvement in the
classification of many malignant neoplasias [1]. However, the
practical impact on lung carcinoma classification has been
comparatively small [2]. In a previous microarray study, we
compared primary lung adenocarcinoma (AC) with squamous cell
carcinoma (SCC) in order to find new immunohistochemical
antibodies that could improve the accuracy of the distinction in
daily practice [3]. Our approach was very robust because cases
included in the analysis were surgical specimens re-classified by
two thoracic pathologists (EC and FL-R) according to the 2004
WHO Classification [4]. One of the top differentially expressed
genes that we found was P63, a well-known marker of squamous
differentiation but, surprisingly, its expression is not widely used
for this purpose in pathology laboratories worldwide. Indeed, this
result was validated with a tissue microarray (TMA) (Fig. 1 and
Table 1).
Nowadays we are facing a situation in which some new targeted
agents should not be used in SCCs, not only because they do not
provide better response rates (pemetrexed), but also because their
use in this histological type is associated with life-threatening
complications (i.e. bevacizumab) [5–7]. To further complicate the
field, other agents (i.e., anti-IGFR) might only (or preferably)
increase the response rate of SCC [8].
Given the recent need to identify lung SCCs, we tried to further
confirm our previous findings in another independent series. At
the same time, we sought to investigate the feasibility of this
approach to reduce the ‘‘large cell carcinoma (LCC)’’ category in
surgical specimens and to increase the number of specific
diagnoses in a prospective series of small thoracic samples.
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Methods
Ethics Statement
Written informed consent was obtained from all participants
involved. We obtained ethics approval from the ethics committees
at all institutions where samples were analyzed.
Tumor samples and histological characteristics
Small cell lung carcinomas were excluded from the study. Fig. 1
summarizes our methodology, including our published data [3].
To further confirm our P63 microarray data in another
independent cohort (second validation series), we started studying
146 patients who underwent resection of staged pI-II NSCLCs at
‘‘12 de Octubre’’ University Hospital between 1993 and 1997.
Pathological characteristics of the tumors included in the analysis
were as follows: 33 (23%) ACs; 99 (69%) SCCs; 10 (7%) LCCs and
four (3%) sarcomatoid carcinomas (SCs). This study was
performed on TMAs and only P63 IHC was performed. Next,
our aim was to investigate the utility of P63 and also TTF-1
immunostaining to reduce the number of LCC diagnoses on
surgically resected lung specimens. We included 231 patients
(reducing the ‘‘LCC’’ category series) who underwent resection of
staged pI-II NSCLCs at ‘‘12 de Octubre’’ University Hospital
between 1997 and 2003. Pathological characteristics of the tumors
included were as follows: 60 (26%) ACs; 151 (65%) SCCs; and
twenty (9%) LCCs. The study was performed on whole tissue
sections. Afterwards, we investigated the feasibility of the same
approach in a prospective cohort (reducing the ‘‘carcinoma NOS’’
category series) of 66 small thoracic samples (51 bronchoscopic
biopsies and fifteen core-needle biopsies) from the Targeted
Therapies Laboratory at the Madrid Sanchinarro University
Hospital. The classification of the tumors was as follows: 47 (71%)
carcinoma not otherwise specified (NOS); 13 (20%) ACs; and six
(9%) SCCs. Thirty two of the 47 undefined carcinomas (27
bronchoscopic biopsies and five core-needle biopsies) could be
further studied for P63 and TTF-1. In the remaining cases in this
group, all tissue had been previously used for mutation analysis
(data not shown). After clinical evaluation, all but two cases were
considered unresectable. In spite of not having the ‘‘gold
standard’’ of surgical excision, we chose to study this cohort
because it is precisely in patients with advanced lung carcinoma in
which our approach would be most helpful.
Figure 1. Summary of the methodology used in the different series. 1. See reference 3. 2. This series also included 10 large cell carcinomas
and 4 sarcomatoid carcinomas.
doi:10.1371/journal.pone.0012209.g001
Table 1. Validation of P63 IHC as a marker of squamous
differentiation.
1u IHC validation series# 2u IHC validation series
SCC (n = 29) AC (n = 39) SCC (n = 91*) AC (n = 29{)
P63 negative 7 (24%) 29 (74%) 42 (46%) 27 (93%)
P63 positive 22 (76%) 10 (26%) 49 (54%) 2 (7%)
P,0.001 P,0.001
#Published data (see reference 3).
*8 SCCs were not available for immunostaining evaluation.
{4 ACs were not available for immunostaining evaluation.
doi:10.1371/journal.pone.0012209.t001
Table 2. Re-classification of 20 Large cell carcinomas of the
lung by the staining pattern of P63.
Case Initial Diagnosis P63 IHC TTF-1 IHC Final Diagnosis
1 LCC Positive Positive SCC
2 LCC Negative Positive AC
3 LCC Positive Negative SCC
4 LCC Positive Negative SCC
5 LCC Negative Negative Neuroendocrine LCC{
6 LCC Negative Positive AC
7 LCC Positive Positive SCC
8 LCC Positive Negative SCC
9 LCC Negative Positive Neuroendocrine LCC{
10 LCC Positive Negative SCC
11 LCC Negative Positive AC
12 LCC Positive Negative SCC
13 LCC Positive Negative SCC
14 LCC Negative Positive AC
15 LCC Negative Negative Neuroendocrine LCC{
16 LCC Negative Positive AC
17 LCC Negative Positive AC
18 LCC Positive Negative SCC
19 LCC Negative Positive AC
20 LCC Positive Negative SCC
{Cases with neuroendocrine differentiation after histological review, confirmed
by neuroendocrine IHC markers (synaptophysin and CD56).
doi:10.1371/journal.pone.0012209.t002
P63 Immunohistochemistry
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Immunohistochemistry
We performed immunohistochemical (IHC) staining of P63
(4A4, 1:50 dilution; DAKO) in all cohorts. The anti-P63
monoclonal antibody 4A4 recognizes all 6 isoforms (total P63
expression): TAp63a, TAp63b, TAp63c, DNp63a, DNp63b,
DNp63c [9]. IHC staining of TTF-1 (8G7G3/1, 1:200; DAKO)
was also carried out in the last two series. After incubation,
immunodetection was done with the DAKO EnVision Visuali-
zation Method (Dako, Glostrup, Denmark), with diaminobenzi-
dine chromogen as the substrate. Sections were counterstained
with hematoxylin. Immunostaining was evaluated by two
different pathologists (EC and FL-R), using criteria based on
published cut-offs, as follows. P63: scored positive when high
intensity staining was present on $50% of tumor cells; the
remainder was scored negative [10]. TTF-1: scored positive when
staining was present on $5% of tumor cells; the remainder was
scored negative [11]. For both antibodies, only distinct and
intense nuclear staining was considered positive. For all LCCs
with neuroendocrine morphology, immunostaining for CD56
(123C3, 1:50 dilution; DAKO) and synaptophysin (SY38, 1:25
dilution; DAKO) also was performed to confirm neuroendocrine
differentiation.
Statistical analysis
Frequencies were compared either by Fisher’s exact test or by
the X2 contingency test. Differences of p,0.05 were considered
statistically significant. Analyses were performed using the SPSS
program, version 10.0.5 (SPSS Inc, Chicago, IL).
Figure 2. P63 and TTF-1 immunohistochemistry. Cases of LCC (A), carcinoma NOS on bronchoscopic biopsy (B) and carcinoma NOS on core-
needle biopsy (C) are shown. They were all re-classified as SCCs, showing a mutually exclusive pattern: P63 positive and TTF-1 negative. For both
antibodies only distinct nuclear staining was considered positive. High-intensity staining in $50% of tumor cells was scored as positive for P63.
doi:10.1371/journal.pone.0012209.g002
P63 Immunohistochemistry
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Results
Validation of P63 immunohistochemical expression as a
marker of squamous differentiation
Results of P63 expression are summarized in Table 1. In the
first validation series, sensitivity = 0.76, specificity = 0.74, positive
predictive value = 0.69, negative predictive value = 0.81 and
accuracy = 0.75. In the second validation series, two of 29 ACs
(7%) compared with 49 of 91 SCCs (54%) were positive for P63
IHC (p,0.001). Sensitivity, specificity, positive predictive value,
negative predictive value and accuracy were 0.54, 0.93, 0.96, 0.39
and 0.63, respectively.
Value of P63 and TTF-1 immunohistochemistry in
reducing the ‘‘large cell carcinoma’’ category in surgical
specimens
On the basis of our previous results of P63 IHC as a squamous
marker and the published data demonstrating that TTF-1 is
essentially not detected in SCCs, we assessed the utility of both
antibodies for re-classifying 20 LCCs (Table 2) [12,13]. Half of the
20 (50%) LCCs were positive for P63 and were re-classified as
SCCs. All but two P63 positive cases did not express TTF-1
(Fig. 2A). The remaining eight cases were positive for TTF-1 and
seven were considered ACs. Finally, three carcinomas exhibited
features of neuroendocrine differentiation (palisading, necrosis,
high mitotic rate, etc.) that was confirmed with IHC. They were
therefore termed ‘‘large cell neuroendocrine carcinomas’’. All
three were negative for P63, and two of them remained negative
for TTF-1.
Value of P63 and TTF-1 immunohistochemistry in
reducing the ‘‘carcinoma not otherwise specified (NOS)’’
category in small specimens
Results are summarized in Table 3. All P63 positive cases (11/
32, 34%) were diagnosed as SCCs (Fig. 2B and 2C) although two
of them co-expressed TTF-1. All P63 negative tumors were
considered ACs if they showed TTF-1 positivity (13/32, 41%), and
only ‘‘suggestive of AC’’ if this latter antibody was not available (5/
32, 16%). Finally, in three instances both antibodies were negative
(3/32, 9%), and subsequent follow-up was able to identify one
adenocarcinoma and one sarcomatoid carcinoma.
Discussion
We have shown the clinical utility of P63 IHC for the
identification of lung SCCs, further validating our previous
microarray study. That P63 is a marker of squamous differenti-
ation is well known and overexpression of this gene has been
consistently identified in lung SCCs by global gene expression
profiling or by IHC [14–20]. The reported positivity by this latter
method is usually over 80% in most series, but it should be
emphasized that better differentiated areas and even well-
differentiated tumors may be negative [10,12,18,21,22]. This fact
may explain the comparatively low rate of positivity in our two
validation series (Fig. 1 and Table 1) using TMAs (76% and 54%).
Fortunately, this is not a problem in clinical samples because IHC
is not needed in well differentiated SCC. Nonetheless, the
specificity of P63 IHC has been challenged. Although from 0%
to 33% of lung ACs may express P63, negative P63 IHC is used
when researchers need to accurately identify ACs for other
purposes [9,12,21,23–26]. These differences maybe explained by
variability at two phases of the procedure: (1) the antibody that
has been used to detect P63 (analytical phase), and (2) the
interpretation (post-analytical phase) of the staining. The first
possibility is less likely [27]. Although DNp63 isoforms are
frequently expressed in SCCs [28], most of the IHC studies of
P63 expression use antibodies that detect all P63 isoforms
(TAp63a, TAp63b, TAp63c, DNp63a, DNp63b, DNp63c)
[10,27,29,30]. In agreement with other authors, we believe that,
Table 3. Re-classification of 32 carcinomas (NOS) by the
staining pattern of P63 in a prospective series of small
thoracic samples.
Case
Type of
biopsy
Initial
Diagnosis P63 IHC
TTF-1
IHC
Final
Diagnosis
1 Bronchoscopic Carcinoma Negative Negative Carcinoma1
2 Bronchoscopic Carcinoma Positive Negative SCC1
3 Bronchoscopic Carcinoma Positive Negative SCC2
4 Bronchoscopic Carcinoma Positive Negative SCC
5 Bronchoscopic Carcinoma Negative — Suggestive
of AC
6 Core-needle Carcinoma Positive Negative SCC1
7 Bronchoscopic Carcinoma Positive — SCC1
8 Bronchoscopic Carcinoma Positive Negative SCC1
9 Bronchoscopic Carcinoma Negative — Suggestive
of AC3
10 Bronchoscopic Carcinoma Positive — SCC1
11 Bronchoscopic Carcinoma Positive Negative SCC1
12 Bronchoscopic Carcinoma Negative — Suggestive
of AC
13 Bronchoscopic Carcinoma Negative Positive AC
14 Core-needle Carcinoma Negative Positive AC4
15 Bronchoscopic Carcinoma Negative Positive AC
16 Bronchoscopic Carcinoma Negative Positive AC5
17 Bronchoscopic Carcinoma Negative — Suggestive
of AC
18 Bronchoscopic Carcinoma Negative — Suggestive
of AC
19 Bronchoscopic Carcinoma Positive Positive SCC
20 Core-needle Carcinoma Negative Positive AC
21 Bronchoscopic Carcinoma Negative Positive AC3
22 Core-needle Carcinoma Negative Positive AC
23 Bronchoscopic Carcinoma Positive — SCC
24 Bronchoscopic Carcinoma Positive Positive SCC1
25 Bronchoscopic Carcinoma Negative Positive AC4
26 Bronchoscopic Carcinoma Negative Negative Carcinoma6
27 Bronchoscopic Carcinoma Negative Positive AC
28 Bronchoscopic Carcinoma Negative Negative Carcinoma7
29 Bronchoscopic Carcinoma Negative Positive AC
30 Core-needle Carcinoma Negative Positive AC
31 Bronchoscopic Carcinoma Negative Positive AC4
32 Bronchoscopic Carcinoma Negative Positive AC4
1KRAS and EGFR wild type tumour;
2Confirmed after surgical excision;
3Tumour with EGFR gene amplification;
4KRAS mutant tumours (G12C or G12V);
5EGFR mutant tumour (E746-A750del);
6Sarcomatoid carcinoma confirmed after surgical excision;
7AC confirmed in a subsequent pleural effusion.
doi:10.1371/journal.pone.0012209.t003
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from a practical point of view, faint or focal immunostaining for
P63 should be considered non-specific until there is proof that it is
not [10]. Therefore, to increase the specificity of P63 IHC, we
considered a positive result when high intensity staining was
present in $50% of tumor cells [10]. Accordingly, some authors
have demonstrated that when using this approach, fewer ACs are
P63 positive [31]. Ang et al. have recently reported that P63
maybe positive (.20% tumor cells) or focal (#20% tumor cells) in
6% and 23% of ACs, respectively, whereas this tumor type
exhibits very rarely (1.6%) diffuse staining (.50% tumor cells)
[31].
Along these lines, several other approaches have been proposed
to improve the classification of lung carcinomas. Such procedures
include the use of a combination of markers (CD63, P63 and
CD56 or TTF-1, CK 5/6, and P63 or a five-antibody test
comprising TRIM29, CEACAM5, SLC7A5, MUC1, and CK5/
6), the use of novel antibodies (democollin-3) or even microRNA
expression [12,26,30,32,33]. Interestingly, the desmocollin-3
proposal was in fact derived from our microarray study (page
710 in reference 30), because this was indeed the top differentially
expressed gene [3]. We chose to validate P63, in spite of its lower
fold-change, because of the reproducibility of a nuclear staining
and the availability of the antibody (i.e. P63 IHC is routinely used
for assessing the in situ versus infiltrative nature of breast and
prostate carcinomas) [34–36]. Overall, the methodologies taken by
other researchers to raise specificity may also lower the likelihood
of clinical application because of the very limited material that is
usually obtained in bronchoscopic or core-needle biopsies.
Interestingly, another group has recently arrived at similar
conclusions although their specific data is not shown [37].
After we had validated our microarray data in two independent
series, we wanted to address two of the clinically relevant problems
in lung targeted therapies. Both surgically resected and unresect-
able biopsy-proven lung carcinomas with a non-specific diagnosis
(i.e., termed ‘‘LCC’’ in the former case and ‘‘carcinoma NOS’’ in
the latter) may eventually be considered for a targeted therapy that
must exclude SCCs. Assuming, based on our previous evidence,
that P63 positive cases are bona fide SCCs, we were able to
demonstrate the usefulness of P63 IHC in a series of surgically
resected LCCs and in a prospective cohort of small specimens.
One could argue that there is no ‘‘gold standard’’ in these two
situations, which is true, but this approach parallels the real
clinical work. The term ‘‘LCC’’ is defined as one of exclusion and,
as such, this category has been questioned. Indeed, in microarray
experiments these cases belong to either the AC or the SCC group
[20,38]. Therefore, the diagnosis of LCCs is not reproducible and
depends on several uncontrollable parameters (sampling, exper-
tise, etc.). On the other hand, in the real clinical world, we are
constantly asked to refine the ‘‘carcinoma NOS’’ group in order to
guide the oncologist’s therapeutic decision. In our setting, in over
70% of the biopsies of the unresectable lung carcinomas, neither
keratin nor gland formation were identified.
In summary, we have demonstrated how the use of P63 IHC
with rigid interpretation criteria can effectively improve the
identification of SCCs. Targeted therapies in the field of lung
cancer need more reproducible histological diagnoses.
Acknowledgments
We would like to thank the Tumor Bank at the ‘‘Targeted Therapies
Laboratory’’, Madrid Sanchinarro University Hospital, for handling part
of the samples. We thank L. Sa´nchez-Verde from the Immunohistochem-
istry Unit of the CNIO, for performing the first part of the study. This work
was presented in part at the 13th World Conference of Lung Cancer, July
31-August 4, 2009, San Francisco, CA, USA. Translated into English by
Michelle Homden.
Author Contributions
Conceived and designed the experiments: EC BA OT EGG ASG BRV
CM RGL MSC ALE LPA FLR. Performed the experiments: EC BA PR
OT EGG ASG BRV CMRGL ALE LPA FLR. Analyzed the data: EC BA
OT EGG ASG RGL MSC ALE LPA FLR. Contributed reagents/
materials/analysis tools: EC BA PR OT ASG CM RGL ALE LPA FLR.
Wrote the paper: EC BA PR OT EGG ASG BRV CM RGL MSC ALE
LPA FLR.
References
1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000)
Molecular portraits of human breast tumours. Nature 406: 747–752.
2. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, et al. (2006) Gene
expression profiling reveals reproducible human lung adenocarcinoma subtypes
in multiple independent patient cohorts. J Clin Oncol 24: 5079–5090.
3. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, et al. (2008)
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours
and identify selective PIK3CA overexpression by gene amplification. J Pathol
214: 347–356.
4. Brambilla E (2004) In: Travis WD, Brambilla E, Mu¨ller-Hermelink HK,
Harris CC, eds.World Health Organization Classification of Tumours. Pathology
and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC
Press. pp 45–50.
5. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus
pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell
lung cancer. J Clin Oncol 26: 3543–3551.
6. de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, et al. (2008) Lung
Cancer Symptom Scale outcomes in relation to standard efficacy measures: an
analysis of the phase III study of pemetrexed versus docetaxel in advanced non-
small cell lung cancer. J Thorac Oncol 3: 30–36.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-
carboplatin alone or with bevacizumab for non-small cell lung cancer.
N Engl J Med 355: 2542–2550.
8. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, et al. (2009) Phase II
study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871
in combination with paclitaxel and carboplatin in previously untreated, locally
advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516–2522.
9. Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, et al. (2004) P63
expression in lung carcinoma: a tissue microarray study of 408 cases. Appl
Immunohistochem Mol Morphol 12: 240–247.
10. Wu M, Wang B, Gil J, Sabo E, Miller L, et al. (2003) P63 and TTF-1
immunostaining. A useful marker panel for distinguishing small cell carcinoma
of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin
Pathol 119: 696–702.
11. Tan D, Li Q, Deeb G, Ramnath N, Slocum HK, et al. (2003) Thyroid
transcription factor-1 expression prevalence and its clinical implications in non-
small cell lung cancer: a high-throughput tissue microarray and immunohisto-
chemistry study. Hum Pathol 34: 597–604.
12. Kargi A, Gurel D, Tuna B (2007) The diagnostic value of TTF-1, CK 5/6, and
p63 immunostaining in classification of lung carcinomas. Appl Immunohisto-
chem Mol Morphol 15: 415–420.
13. Johansson L (2004) Histopathological classification of lung cancer: relevance of
citokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 8: 259–267.
14. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001)
Classification of human lung carcinomas by mRNA expression profiling reveals
distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98: 13790–13795.
15. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, et al. (2001)
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad
Sci U S A 98: 13784–13789.
16. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, et al. (2004) Tissue-
wide expression profiling using cDNA subtraction and microarrays to identify
tumor-specific genes. Cancer Res 64: 844–856.
17. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, et al. (2003) Non-
small-cell lung cancer molecular signatures recapitulate lung developmental
pathways. Am J Pathol 163: 1949–1960.
18. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, et al. (2004)
Evaluation of immunohistochemical markers in non-small cell lung cancer by
unsupervised hierarchical clustering analysis: a tissue microarray study of 284
cases and 18 markers. J Pathol 204: 101–109.
19. Ullmann R, Morbini P, Halbwedl I, Bongiovanni M, Gogg-Kammerer M, et al.
(2004) Protein expression profiles in adenocarcinomas and squamous cell
P63 Immunohistochemistry
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12209
carcinomas of the lung generated using tissue microarrays. J Pathol 203:
798–807.
20. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, et al. (2010) Gene
expression-based classification of non-small cell lung carcinomas and survival
prediction. PLoS One 5: e10312.
21. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, et al. (2003)
Significance of p63 amplification and overexpression in lung cancer develop-
ment and prognosis. Cancer Res 63: 7113–7121.
22. Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, et al. (2009) Expression of
podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci
100: 2054–2059.
23. Sheikh HA, Fuhrer K, Cieply K, Yousem S (2004) P63 expression in assessment
of bronchioloalveolar proliferations of the lung. Mod Pathol 17: 1134–1140.
24. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, et al. (2002)
P63 immunoreactivity in lung cancer: yet another player in the development of
squamous cell carcinomas? J Pathol 198: 100–109.
25. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique
clinicopathologic features characterize ALK-rearranged lung adenocarcinoma
in the western population. Clin Cancer Res 15: 5216–5223.
26. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, et al. (2009) Diagnostic
assay based on hsa-miR-205 expression distinguishes squamous from non-
squamous non-small-cell lung carcinoma. J Clin Oncol 27: 2030–2037.
27. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F (2006) Expression
of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung
carcinomas. Hum Pathol 37: 542–546.
28. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, et al. (2002)
Differential expression of p63 isoforms in normal tissues and neoplastic cells.
J Pathol 198: 417–427.
29. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, et al. (2002) P63 in pulmonary
epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
Hum Pathol 33: 921–926.
30. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, et al. (2009)
Desmocollin-3: a new marker of squamous differentiation in undifferentiated
large-cell carcinoma of the lung. Mod Pathol 22: 709–717.
31. Ang DC, Ghaffar H, Zakowski MF, Teruya-Feldstein J, Moreira AL, et al.
(2010) Expression of Squamous Markers in Lung Adenocarcinoma (AD):
Clinicopathologic and Molecular Correlates, and Implications for Differentia-
tion from Squamous Cell Carcinoma (SqCC). Available: http://www.
abstracts2view.com/uscap10/view.php?nu=USCAP10L_1770.
32. Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, et al. (2009) A novel
five-antibody immunohistochemical test for subclassification of lung carcinoma.
Mod Pathol 22: 1032–1043.
33. Kim DH, Kwon MS (2010) Role of fine needle aspiration cytology, cell block
preparation and CD63, P63 and CD56 immunostaining in classifying the
specific tumor type of the lung. Acta Cytol 54: 55–59.
34. Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin
5/6 as immunohistochemical markers for the differential diagnosis of poorly
differentiated and undifferentiated carcinomas. Am J Clin Pathol 116: 823–830.
35. Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical
distinction of invasive from noninvasive breast lesions: a comparative study of
p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol
27: 82–90.
36. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, et al. (2004) Usefulness of
basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate
glandular proliferations. Am J Clin Pathol 122: 517–523.
37. Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G (2009) Morphology
and a limited number of immunohistochemical markers may efficiently subtype
non-small-cell lung cancer. J Clin Oncol 27: 141–142.
38. Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, et al. (2003) A
training-testing approach to the molecular classification of resected non-small
cell lung cancer. Clin Cancer Res 9: 4695–4704.
P63 Immunohistochemistry
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12209
